



STATE OF WEST VIRGINIA
DEPARTMENT OF HEALTH AND HUMAN RESOURCES

Bob Wise
Governor

Paul L. Nusbaum
Secretary

West Virginia Department of Health and Human Resources
Bureau for Medical Services
Pharmaceutical and Therapeutics (P & T) Committee
October 17, 2007 – 3:00 p.m. – 5:00 p.m.
Diamond Building
Rooms B10 & B11
Charleston, West Virginia

MINUTES

Members Present:

David Avery, M.D.
Steven R. Matulis, M.D.
Michael Grome, PA-C
Scott Brown, R.Ph.
Rodney Fink, D.O.
Teresa Frazer, M.D., FAAP
Ahmed Faheem, M.D.
Jeffrey Ashley, M.D.
James Bartsch, R.Ph. - Conference
Gretchen Oley, M.D. - Conference
Teresa Dunsworth, PharmD - Conference

Members Not Present

Harriet Nottingham, R. Ph.
Barbara Koster, MSN, RNC-ANP
Robert Stanton, PharmD

DHHR/BMS Staff Present

Peggy King, Pharmacy Director
Gail Goodnight, Rebate Coordinator
Vicki Cunningham, DUR Coordinator
Lynda Edwards, Secretary

Contract Staff Present:

Steve Liles, PharmD, Provider Synergies
Laureen Biczak, DO, GHS
Jim Clair, GHS
Tim Clifford, MD, GHS
John Grotton, R.Ph., GHS

Other Contract Staff/State Staff Present:

Stephen Small, RDTP

I. Call to Order

Dr. Steven Matulis, Chairperson, called the meeting to order at 3:15 p.m.

II. Housekeeping

Peggy King, R.Ph., Pharmacy Director, was recognized, and she advised the audience on how the meeting would be conducted.

Ms. King stated that it was time to nominate a new Chairperson and Vice Chairperson for the Committee. Dr. Avery was nominated for Chairperson. Scott Brown was nominated for Vice Chairperson. A motion was made to close nominations and seconded. Votes were taken and the motion carried. The Committee voted unanimously for Dr. Avery, Chairperson, and Scott Brown, Vice Chairperson.

Ms. King presented the new Chairpersons a copy of Parliamentary Procedures handout. All members requested a copy of the handout.

III. Introductions

All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

IV. Approval of Minutes of August 22, 2007 Meeting

Chairman Matulis asked for approval of the minutes from the last meeting. A motion was made and seconded, votes were taken and the motion carried to approve the minutes as submitted.

V. Mission Statement

Ms. King discussed the Social Security Act, Federal regulations, and policies for coverage of drugs for Medicaid members. She stated that she would e-mail this to the members so they could access the different sections more easily. She said that the Bureau has to follow guidelines that are set by CMS and the Inspector General's Office. She said if there were questions they could be e-mailed to her.

Ms. King requested that the Committee adopt a Mission Statement. She asked that the members review a draft statement that was included in their packet and e-mail their comments to her to be compiled for the next meeting.

VI. Provider Synergies Presentation

Steve Liles, Provider Synergies, gave a presentation on class information and savings figures for the year. He said the Preferred Drug List (PDL) saved the State over \$35,700,000 for the period 3rd Quarter 2006 through 2nd Quarter 2007.

He explained that only three percent of the drugs listed on the PDL that were utilized by West Virginia Medicaid members were non-preferred, and from a clinical stand point, the Committee has done a good job of developing the PDL that meets the needs of the members as well as the providers.

He then discussed the amount of utilization for each class of drugs. He stated that the Committee wanted Provider Synergies to monitor generic pricing for the mandatory generic substitution policy. Dr. Liles stated that some of the generics have decreased in price. Provider Synergies recommended moving generic Norvasc (amlodipine), generic Zofran (ondansetron), generic Lamisil (terbinafine), generic Coreg (carvedilol), and generic Lotrel (benazepril/amlodipine) to preferred status, and leave the status of the branded products unchanged for now. A motion was made to accept the recommendations by Provider Synergies, the motion was seconded. Dr. Liles stated that the only brand that was not preferred was Norvasc but the Committee could keep the generic and leave the brand as non-preferred. The motion was corrected to accept all generics as stated by Provider Synergies, motion was seconded, votes were taken and the motion carried.

VII. Next Meeting Date – February 6, 2007 (Charleston Civic Center)

Chairman Matulis informed the audience that the next meeting will be held on February 6, 2008. Mrs. King said that the meeting starts at 9:00 a.m. at the Charleston Civic Center.

Ms. King stated that we will be looking into changing the speaker sign-up process and to look at the website in the future for any changes.

VIII. Introduction of New Vendor (GHS)

Ms. King stated that State Purchasing laws and regulations required the Bureau to put out for bid any contract that is greater than \$10,000. She explained the bidding and RFP process. She said the contract was awarded to Goold Health Systems d.b.a. GHS Data Management. She thanked Provider Synergies for all the work that has been done. She said that the Bureau has a wonderful product due to their hard work and the Committee's input.

GHS introduced the team members: Jim Clair, Chief Executive Officer, Tim Clifford, M.D., Lauren Biczak, D.O, and John Grotton, R.Ph. Mr. Clair explained the clinical review process and the monograph they will be providing. He also explained the Sovereign States Drug Consortium (SSDC) multi-state pool. After summarizing the process for supplemental rebate offers from the manufacturers, Mr. Clair discussed the possibility of West Virginia Medicaid joining the pool and having an annual review of the Preferred Drug List. There was a lengthy discussion about the reviews needed for new drugs, having only one PDL change per year, and deadlines for submission of offers by pharmaceutical companies. Ms. King stated that it would be good business to become part of the multi-state pool and be eligible to receive larger discounted offers on the PDL.

Ms. King stated that Pharmacy is an optional benefit, and in order for it to be affordable, the Bureau has had to use various tactics to reduce the rate of increase. She said that many people in the State that have no prescription drug coverage, and the Bureau must keep working to control costs while drug prices continue to rise. She said the PDL is a cost-containment exercise.

One of the Committee members asked if the meeting materials could be delivered to the Committee on CD-rom or flash drives. Ms. King said she would explore this for the Committee.

It was also asked if the Prior Authorization Process could be web-based. Ms. King responded that the Bureau would also explore this possibility.

IX. Open to the Floor

The meeting was then opened for comments from the audience. There were no comments.

The Committee members thanked Steve Liles and Provider Synergies for all the work they have done with the Preferred Drug List.

There was a discussion about collaboration with the Drug Utilization Review (DUR) Committee. Dr. Avery volunteered to go to the next DUR meeting. Vicki Cunningham, DUR Coordinator, stated that she would send the P & T Committee the minutes from the DUR Meeting.

Ms. King stated that the format for the February meeting may be changed asked if the Committee would be interested in a report from Rational Drug Therapy Program regarding prior authorizations for non-preferred drugs. One of the members said to just give them the report in a hard copy and if they have any questions they can ask them later.

Ms. Cunningham said the Rational Drug Therapy Report is part of the DUR Minutes and that the Committee will receive that report that the DUR Committee receives quarterly.

The Committee thanked Dr. Matulis for his term as Chairperson of the P & T Committee.

X. Executive Session

The Committee decided not to have the Executive Session.

XI. Adjournment

A motion was made, was seconded, votes were taken and the motion carried to adjourn the meeting of the Pharmaceutical and Therapeutics Committee.